Teck Resources (NYSE:TECK) 주식

Teck Resources

Teck is a base metals miner with copper and zinc operations in Canada, the United States, Chile, and Peru. After selling its metallurgical coal business, copper is now its major commodity by EBITDA contribution, followed by zinc. Teck is a top-three zinc miner. Its major new copper mine in Chile at the majority-owned Quebrada Blanca 2, in partnership with Sumitomo, will drive an increase in Teck's attributable copper production by roughly 75%. Along with a number of additional copper growth options, Teck's strategy is to rebalance its portfolio to low-carbon metals such as copper. It sold its oil sands business in early 2023 and its coal business in mid-2024.

Copper. Shutterstock

Long Ideas

Specialty ETFs

Commodities

Markets

Trading Ideas

ETFs

COPX

CPER

ICOP

LUNMF

TECK

전 세계가 전기화된 미래로 나아가면서 구리 시장은 중요한 기로에 서 있다. JP모건의 애널리스트인 패트릭 존스(Patrick Jones), 그렉 시어러(Greg Shearer) 및 빌 피터슨(Bill Peterson)의 통찰은 구리 가격에 대한 단기적인 장애물과 전기차 및 공급 동태의 변화에 의해 주도되는 화려한 장기 전망을 제시한다.

구리의 고공행진: EV, 신기술이 이 금속의 다음 대혁명을 이끌 수 있을까?

Teck Resources Ltd

TECK RESOURCES LTD ORD by Teck Resources Ltd.

Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the <a href="https://pr.report/9xgt">Annual ELITE PED-GI Congress</a>; Click <a href="https://pr.report/9xgu">here</a> to register
There are no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management including total parenteral nutrition (TPN) - which carries the risk of morbidity, infections, metabolic complications, liver and kidney problems, and neurodevelopmental delay
This proof-of-concept data in MVID supports crofelemer's potential inclusion in the European Medicines Agency's (EMA) <a href="https://pr.report/9xgv">PRIME</a> program for expediated and assisted regulatory approval in the EU as well as FDA's <a href="https://pr.report/9xgw">Breakthrough Therapies</a> program for expedited regulatory approval in the US
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 30, 2025 / <a href="https://pr.report/9xgb">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/9xgd">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/9xge">Napo Therapeutics</a> today announced initial proof-of-concept results showing that a novel liquid formulation of crofelemer reduced the required TPN and/or supplementary intravenous fluids, collectively referred to as parenteral support (PS) in patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) by up to 27% and 12.5% respectively. In addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output - an indicator of improved nutrient oral absorption.

News

JAGX

Jaguar Health Reports Encouraging Proof-of-Concept Results For Crofelemer In MVID And SBS-IF Patients

WIIM

SAGT

Sagtec Global shares are trading higher after the company reported a year-over-year increase in FY24 financial results.

Initial trial phase ("PoC 1") achieved key learnings and met all study objectives
Clinically meaningful pain reduction with 100% of responders achieving zero opioid use at 7 days post-procedure and 73% of responders remaining opioid free at 4-6 week follow-up
Company has initiated market expansion study ("PoC 2") of additional visceral cancers, and earlier stage pancreatic cancer, to begin in Q2 2025
Additional indications potentially double the addressable market beyond pancreatic cancer pain
&nbsp;

Biotech

General

AMIX

Autonomix Medical Reports Outcomes In Initial Phase Of First-in-Human Proof-of-Concept Trial In Pancreatic Cancer Pain And Initiates Market Expansion Study for Visceral Cancer Pain

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Hold to Hold.

Reiteration

Analyst Ratings

SAGE

Needham Reiterates Hold on Sage Therapeuticsto Hold

PPBT

Purple Biotech shares are trading higher after the company's CM24 showed up to a 90% reduction in the death risk for pancreatic cancer patients and announced it will commence a Phase 2b study.

Earnings

Sagtec Global FY24 EPS $0.14 Up From $0.09 YoY; Revenue $11.6M Up From $6.5M YoY

Ocean Power Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>) ("OPT" or the "Company"), a leader in innovative, cost-effective, low-carbon and artificial intelligence maritime services that enable safer and more productive ocean operations and related power, data, and service solutions, today announced the shipment of a WAM-V&#xAE; 22' with autonomous capabilities designed to provide offshore surveys with 24/7 operational payloads for multiple days without requiring a return to base.

OPTT

Ocean Power Technologies Ships Autonomous WAM-V 22 For Multi-Day Offshore Surveys

CERo Therapeutics Holdings, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that TriStar Centennial Medical Center, through Sarah Cannon Research Institute (SCRI), in Nashville, Tennessee, is a clinical trial site for the Company's Phase 1 clinical of CER-1236. Collaborating with SCRI to advance cancer research, TriStar Centennial offers innovative clinical research trials for various disease indications. The trial is focused on patients with acute myeloid leukemia (AML), and patient enrollment is underway, with expected dosing of the first patient during the first half of 2025.&nbsp;

CERO

CERo Therapeutics Announces TriStar Centennial Medical Center As Clinical Trial Site For Phase 1 Clinical Of CER-1236

RCKY

Rocky Brands shares are trading higher after the company reported better-than-expected Q1 financial results.

Telsey Advisory Group analyst Joseph Feldman maintains Holley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NYSE">HLLY</a>) with a Outperform and maintains $4.5 price target.

Price Target

HLLY

Telsey Advisory Group Maintains Outperform on Holley, Maintains $4.5 Price Target

Western Digital Declares Quarterly Dividend Of $0.10 Per Share Of The Company's Common Stock, Payable On June 18 To Shareholders Of Record As Of June 4

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Wednesday.
Shares of Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) fell sharply in today's pre-market trading as the company reported weaker-than-expected <a href="https://www.benzinga.com/25/04/45090652/starbucks-says-simple-everyday-luxury-is-here-to-stay-as-people-still-want-small-indulgences-amid-belt-tightening">second-quarter financial results</a>.
The coffee giant reported second-quarter adjusted earnings of 41 cents per share, missing analyst estimates of 50 cents per share.
Starbucks shares dipped 6.5% to $79.33 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) shares dipped 17.4% to $2.52 in pre-market trading. InnovAge will announce fiscal third quarter 2025 financial results and host conference call Tuesday, May 6.</li>
<li>Tenable Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) shares fell 17% to $27.95 in pre-market trading after the company cut its FY25 sales guidance.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) declined 15.1% to $30.57 in pre-market trading after the company lowered its preliminary guidance.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) dipped 13.5% to $7.87 in pre-market trading as the company reported first-quarter financial results and announced it will not provide second-quarter guidance.</li>
<li>Wabash National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNC#NYSE">WNC</a>) fell 13.3% to $8.64 in pre-market trading following weaker-than-expected quarterly results.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) dipped 13.1% to $119.25 in pre-market trading after the company reported worse-than-expected first-quarter EPS results and cut its FY25 guidance.</li>
<li>Unum Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) tumbled 9.1% to $72.00 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Vicor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VICR#NASDAQ">VICR</a>) fell 7.3% to $48.12 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Garmin Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NASDAQ">GRMN</a>) declined 5.4% to $193.00 in pre-market trading after posting weak earnings.</li>
<li>Bausch + Lomb Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) fell 5.3% to $12.99 in pre-market trading following downbeat first-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Movers

BLCO

FSLR

GRMN

INNV

SBUX

SMCI

SNAP

TENB

VICR

Starbucks Posts Weak Earnings, Joins Super Micro Computer, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

IMUX

Immunic shares are trading lower. The company reported Phase 2 data from its CALLIPER trial.

Blue Foundry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFY#NASDAQ">BLFY</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is unchanged from the same period last year. The company reported quarterly sales of $11.14 million which beat the analyst consensus estimate of $10.29 million by 8.20 percent. This is a 12.87 percent increase over sales of $9.87 million the same period last year.

Earnings Beats

BLFY

Blue Foundry Q1 EPS $(0.13) Beats $(0.17) Estimate, Sales $11.14M Beat $10.29M Estimate

AIMD

AIMDW

Ainos Partners With ASE Chung Li To Power AI Scent Digitization In Smart Manufacturing

Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) is looking for Q4 Adj EPS of $1.25-$1.65 vs $1.16 analyst estimate. sees sales of $2.300 billion-$2.600 billion vs $2.39 billion analyst estimate.

Guidance

Western Digital Sees Q4 Adj EPS $1.25-$1.65 vs $1.16 Est; Sees Sales $2.300B-$2.600B vs $2.39B Est

STSS

Sharps Technology shares are trading higher after the company announced it received a $400K initial purchase order from an IV flushing solutions business.

Macro Economic Events

Macro Notification

Econ #s

Economics

ADP Nonfarm Employment Change (Apr) 62K vs 114K Est.; Prior 155K

Semple, Marchal &amp; Cooper (SM&amp;C) has reportedly been expelled from a national accountancy alliance due to its association with Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), according to a recent lawsuit.
What Happened: SM&amp;C assumed the role of auditor for TMTG in May 2024, following the closure of TMTG&#8217;s previous accounting firm for fraudulent activities. This new client relationship led to a dispute with BDO Alliance USA, a software and training provider for SM&amp;C since 1994, <a href="https://www.ft.com/content/9b26a1c8-b953-43b6-8885-6133b31f6a6a">reported</a> the Financial Times.
BDO Alliance USA is one of the largest networks of accounting and professional service firms, comprising over 900 independent firm locations across nearly every U.S. state and offering a wide range of services.
The lawsuit claims that BDO, the sixth-largest accounting firm in the U.S. by revenue, threatened to terminate SM&amp;C's membership in its alliance if the firm didn't cut ties with TMTG. BDO carried out this threat, terminating the relationship on June 30, 2024.
BDO executive Michael Horwitz reportedly justified the firm&#8217;s stance by stating, &#8220;Because he [the principal shareholder] is a criminal!&#8221; At the time, Donald Trump, the majority stakeholder in TMTG, was facing a trial in New York for falsifying business records.
The lawsuit further claims that SM&amp;C&#8217;s expulsion from the alliance forced it to overhaul&nbsp;its documents and materials and&nbsp;retrain its employees, resulting in substantial financial costs.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/equities/25/04/45090925/trumps-call-to-jeff-bezos-over-amazons-tariff-display-plans-draws-criticism-from-peter-schiff-th" target="_blank" rel="noreferrer noopener">Trump&#8217;s Call To Jeff Bezos Over Amazon&#8217;s Tariff Display Earns Peter Schiff&#8217;s Ire: &#8216;Type Of Stuff You Might Expect To See In China&#8217;</a>
Why It Matters: The controversy surrounding TMTG has been escalating in recent times. Earlier this month, the company faced a&nbsp;<a href="https://www.benzinga.com/markets/equities/25/04/44832068/trump-media-technology-group-faces-106-million-short-bet-from-hedge-fund-as-shares-plunge-to-six-month-low">$106 million short bet</a>&nbsp;from a London-based hedge fund, Qube Research &amp; Technologies Limited, as its shares plunged to a six-month low.
The expulsion of SM&amp;C from the national accountancy alliance adds another layer to the ongoing saga, highlighting the potential reputational risks for firms associated with TMTG.
Meanwhile, TMTG has announced plans to launch a <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45090007/trump-media-says-its-exploring-utility-token-within-truth-digital-wallet-as-part-of-reward">utility token</a> for users accessing its Truth Social ecosystem, as part of a rewards program. This move was seen as an attempt to revitalize the company&#8217;s fortunes amid the ongoing legal and financial challenges.
DJT stock climbed nearly 28% over the past month. On Tuesday, it closed 3.29% lower to close at $24.98, as per <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>. 
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/03/44211508/mark-cuban-once-questioned-whether-donald-trump-is-really-a-billionaire" target="_blank" rel="noreferrer noopener">Mark Cuban Once Questioned Whether Donald Trump Is Really a Billionaire, Here's What He Said &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Arizona Firm Expelled From National Alliance Over Ties With Trump Media, Lawsuit Reveals

Telsey Advisory Group analyst Dana Telsey maintains Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Market Perform and lowers the price target from $38 to $24.

SHOO

Telsey Advisory Group Maintains Market Perform on Steven Madden, Lowers Price Target to $24

Comments

Teck Resources

뉴스

파트너 / 기고자

벤징가 글로벌